Inform Genomics, a private company, was founded with the mission to revolutionize personalized medicine for cancer supportive care and inflammatory diseases. They focus on developing innovative diagnostic products that utilize genome-wide association studies and proprietary analytic methods. Their primary offerings are single-source laboratory tests based on SNP clusters, designed to predict individual patient outcomes to various treatments. This approach aims to enhance personalized patient care and improve clinical outcomes.

Notable figures associated with Inform Genomics include experts in genomics and personalized medicine, although specific names are not publicly highlighted. The company has attracted significant interest from investors in the biotech sector due to its pioneering approach. Key achievements include the successful development of their proprietary genomic analysis platform and the launch of their initial diagnostic tests. Inform Genomics' impact lies in its potential to transform patient care by providing tailored treatment strategies based on genetic profiles, thereby improving the efficacy of medical interventions.